Specifically, EnvisionRx could account for 28 percent of adjusted EBITDA after the deal with Walgreens closes, which would be up from 19 percent in the first quarter of 2017. Bottom line, investors should consider the deal with Walgreens as a "re-launch" of the company's turnaround efforts but the company needs to show improvements before investors can become aggressive. At time of publication, shares of Rite Aid were down 4.42 percent at $2.38. Walgreens shares were up 1.26 percent at $83.32. Related Links: Prescribing A Pharmacy Trade: Walgreens Vs. CVS Vs.